Aaron W. Sigler

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
“For-cause” inspections are initiated during the review of bioequivalence (BE) data submitted to Abbreviated New Drug Applications when possible scientific misconduct and study irregularities are discovered. We investigated the common reasons for initiating “for-cause” inspections related to the clinical, analytical, and dissolution study sites associated(More)
  • 1